We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Elanco Animal Health (ELAN) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Elanco Animal Health Incorporated (ELAN - Free Report) to post quarterly earnings of $0.15 per share in its upcoming report, which indicates a year-over-year increase of 87.5%. Revenues are expected to be $1.01 billion, down 2.2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $428.67 million. The estimate suggests a change of +3.1% year over year.
Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $9.35 million. The estimate indicates a change of +3.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Total Farm Animal' should come in at $575.40 million. The estimate points to a change of -5.7% from the year-ago quarter.
Shares of Elanco Animal Health have demonstrated returns of -8.8% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), ELAN is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Elanco Animal Health (ELAN) Q4 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Elanco Animal Health Incorporated (ELAN - Free Report) to post quarterly earnings of $0.15 per share in its upcoming report, which indicates a year-over-year increase of 87.5%. Revenues are expected to be $1.01 billion, down 2.2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $428.67 million. The estimate suggests a change of +3.1% year over year.
Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $9.35 million. The estimate indicates a change of +3.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Total Farm Animal' should come in at $575.40 million. The estimate points to a change of -5.7% from the year-ago quarter.
View all Key Company Metrics for Elanco Animal Health here>>>
Shares of Elanco Animal Health have demonstrated returns of -8.8% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), ELAN is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>